Streetbeat News

Products Services

ITOS

iTeos Therapeutics has outlined its strategic priorities for 2024, including anticipated clinical data readouts for its TIGIT program and adenosine portfolio. The company expects its cash balance of $644.9M as of September 30, 2023, to fund operations through 2026. Key milestones include Phase 2 trials for belrestotug + dostarlimab in 1L NSCLC and 1L HNSCC, and Phase 2 and Phase 1 trials for inupadenant and EOS-984, respectively.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:45 pm

JNVR

Janover Inc (NASDAQ:JNVR) has launched Janover Insurance Group, a new insurtech subsidiary. The venture will integrate with Janover's AI applications and marketing funnel, which has over 88 million annual impressions on Google. This integration is expected to provide broad distribution and operational efficiencies. Janover Insurance Group will initially focus on multifamily and commercial property insurance, with plans to expand to SMB clients. The company aims to transform commercial property insurance using generative AI and data access. Tyler Schapiro, CEO of Flagler Insurance, has been tapped as a strategic advisor to enhance the subsidiary's expertise.

Portfolio Pulse from Anusuya Lahiri

January 08, 2024 | 1:45 pm

JNVR

Janover has launched its insurtech startup, Janover Insurance Group, according to an exclusive report by Benzinga.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:45 pm

ORIC

ORIC Pharmaceuticals announced initial Phase 1b data for its product ORIC-944, highlighting a potential best-in-class profile with a half-life greater than 10 hours, robust target engagement, and a well-tolerated safety profile. The company plans to advance the product for combination development.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:44 pm

BTCUSD

A study by Coingecko Research based on Google Trends data from January 2019 to January 2024 shows Luxembourg, St. Helena, Singapore, and Switzerland have the highest interest in Bitcoin ETFs, surpassing the US, which ranks 12th. The US shows relatively even interest across states, with Nevada leading. The study also notes that 4 of the top 15 interested countries already have spot Bitcoin ETFs. BTC price is up 1.6% at $45,003.

Portfolio Pulse from Mehab Qureshi

January 08, 2024 | 1:42 pm

IRTC

iRhythm Technologies, Inc. (NASDAQ:IRTC) reported preliminary Q4 2023 results at the J.P. Morgan Healthcare Conference, showing over 22% YoY growth in patient registrations. The company expects FY24 revenue to be between $575M-$585M, aligning with estimates. iRhythm published the CAMELOT study, submitted a 510(k) to the FDA, received CE marks for Zio Monitor and ZEUS systems, and closed a $150M term loan credit facility with Braidwell LP. The company is focusing on expanding its cardiology and primary care channels and international markets, while investing in technology and growth.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:41 pm

HSAI

Hesai Technology (NASDAQ:HSAI) announced two new ADAS lidar products, the AT512 and ET25, and the completion of its 'Maxwell' R&D and manufacturing center. The AT512 offers a 300m range at 10% reflectivity, with a record 12.3 million points per second, while the ET25 is an ultra-thin lidar with a 250m range. The 'Maxwell' center features advanced lidar testing and smart industrial robots for automated production. Hesai has also won a lidar design contract with a global OEM and has delivered 300,000 units to date, with 50,000 in December alone.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:39 pm

LQDA

UTHR

Liquidia Corporation has responded to a patent infringement lawsuit by United Therapeutics, seeking dismissal of all claims related to the '793 patent due to prior invalidity findings affirmed by the Federal Circuit. Liquidia also filed counterclaims asserting the '327 patent is not infringed, invalid, and unenforceable, alleging United Therapeutics failed to disclose prior art during patent prosecution. The dispute centers around Liquidia's NDA for YUTREPIA, an inhalation powder for treating pulmonary hypertension. Liquidia argues against a 30-month regulatory stay, as the patents were not issued before the original NDA filing.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:38 pm

VERU

Veru Inc. has submitted an Investigational New Drug (IND) application to the FDA for the development of Enobosarm, a drug aimed at preventing muscle loss and promoting fat loss in combination with GLP-1 drugs for weight loss. This submission marks a step forward in the company's efforts to address the needs of individuals seeking weight loss solutions that also preserve muscle mass.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:38 pm